1 |
Huang Z, Dewanjee S, Chakraborty P, Jha NK, Dey A, Gangopadhyay M, Chen XY, Wang J, Jha SK. CAR T cells: engineered immune cells to treat brain cancers and beyond. Mol Cancer 2023;22:22. [PMID: 36721153 DOI: 10.1186/s12943-022-01712-8] [Reference Citation Analysis]
|
2 |
Brookens SK, Posey AD Jr. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations. Cancer J 2023;29:28-33. [PMID: 36693155 DOI: 10.1097/PPO.0000000000000636] [Reference Citation Analysis]
|
3 |
Liu Y, An L, Huang R, Xiong J, Yang H, Wang X, Zhang X. Strategies to enhance CAR-T persistence. Biomark Res 2022;10:86. [PMID: 36419115 DOI: 10.1186/s40364-022-00434-9] [Reference Citation Analysis]
|
4 |
Castiello L, Santodonato L, Napolitano M, Carlei D, Montefiore E, Monque DM, D’agostino G, Aricò E. Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe. Cancers 2022;14:5351. [DOI: 10.3390/cancers14215351] [Reference Citation Analysis]
|
5 |
Mao R, Kong W, He Y. The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better. Front Immunol 2022;13:1032403. [DOI: 10.3389/fimmu.2022.1032403] [Reference Citation Analysis]
|
6 |
Qian W, Gao J, Zhang J, Lei W, Zhao A, Liu H, Yang C, Wei C, Guo S, Chen Z, Guo Q, Li L, Zhao M, Wu G. Safety and Feasibility of Anti-CD19 CAR T Cells Expressing Inducible IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-cell Lymphoma.. [DOI: 10.21203/rs.3.rs-2124394/v1] [Reference Citation Analysis]
|